Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking.

Co-delivery of siRNA and chemotherapeutic agents has been developed to combat multidrug resistance in cancer therapy. Recently, we developed a series of quantum dots (QDs) functionalized by β-cyclodextrin (β-CD) coupled to amino acids, some of which can be used to facilitate the delivery of siRNA. In this study, two CdSe/ZnSe QDs modified with β-CD coupled to L-Arg or L-His were used to simultaneously deliver doxorubicin (Dox) and siRNA targeting the MDR1 gene to reverse the multidrug resistance of HeLa cells. In this co-delivery system, Dox was firstly encapsulated into the hydrophobic cavities of β-CD, resulting in bypass of P-glycoprotein (P-gp)-mediated drug efflux. After complex formation of the mdr1 siRNA with Dox-loaded QDs via electrostatic interaction, significant down-regulation of mdr1 mRNA levels and P-gp expression was achieved as shown by RT-PCR and Western blotting experiments, respectively. The number of apoptotic HeLa cells after treatment with the complexes substantially exceeded the number of apoptotic cells induced by free Dox only. The intrinsic fluorescence of the QDs provided an approach to track the system by laser confocal microscopy. These multifunctional QDs are promising vehicles for the co-delivery of nucleic acids and chemotherapeutics and for real-time tracking of treatment.

[1]  F. Hirayama,et al.  Pharmaceutical Applications of Cyclodextrins and Their Derivatives , 2006 .

[2]  J. French,et al.  Rational polytherapy , 2009, Epilepsia.

[3]  Jian Zhang,et al.  The establishment of two paclitaxel‐resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines , 2007, The Prostate.

[4]  Ho Sup Yoon,et al.  Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer , 2006, Nature materials.

[5]  Liang-Nian Ji,et al.  Targeted cellular uptake and siRNA silencing by quantum-dot nanoparticles coated with β-cyclodextrin coupled to amino acids. , 2011, Chemistry.

[6]  Zheng-Rong Lu,et al.  Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. , 2009, Biomaterials.

[7]  J. H. Cross,et al.  The surgical treatment of Landau‐Kleffner syndrome , 2009, Epilepsia.

[8]  S. Mirski,et al.  Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. , 1987, Cancer research.

[9]  J. Riordan,et al.  Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines , 1985, Nature.

[10]  Hua Su,et al.  Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracellular imaging. , 2011, Biomaterials.

[11]  V. Stella,et al.  Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. , 1996, Journal of pharmaceutical sciences.

[12]  Q. Yao,et al.  Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. , 2008, Expert opinion on therapeutic targets.

[13]  S. Ambudkar,et al.  Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges , 2008, Expert opinion on drug metabolism & toxicology.

[14]  P. Choong,et al.  A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy. , 2009, Biomaterials.

[15]  Mark E. Davis,et al.  Cyclodextrin-based pharmaceutics: past, present and future , 2004, Nature Reviews Drug Discovery.

[16]  E. Wang,et al.  HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein , 2001, Pharmaceutical Research.

[17]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[18]  U. Gündüz,et al.  Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells , 2011, Cancer Chemotherapy and Pharmacology.

[19]  T. Minko,et al.  Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. , 2008, Nanomedicine.

[20]  Liang-Nian Ji,et al.  Synthesis, biocompatibility and cell labeling of L-arginine-functional beta-cyclodextrin-modified quantum dot probes. , 2010, Biomaterials.

[21]  Hua Ai,et al.  The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. , 2011, Biomaterials.

[22]  D. Kerr,et al.  Clinical trials of P-glycoprotein reversal in solid tumours. , 1996, European journal of cancer.

[23]  V. Torchilin,et al.  Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. , 2009, Molecular pharmaceutics.

[24]  Zongxi Li,et al.  Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. , 2010, ACS nano.

[25]  B. Szende,et al.  Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators. , 2001, Cancer letters.

[26]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.